Fiche publication
Date publication
avril 2022
Journal
Genes
Auteurs
Membres identifiés du Cancéropôle Est :
Dr HERMETET François
,
Pr GIRODON François
Tous les auteurs :
Regimbeau M, Mary R, Hermetet F, Girodon F
Lien Pubmed
Résumé
Polycythemia vera belongs to myeloproliferative neoplasms, essentially by affecting the erythroblastic lineage. JAK2 alterations have emerged as major driver mutations triggering PV-phenotype with the mutation detected in nearly 98% of cases. That's why JAK2 targeting therapeutic strategies have rapidly emerged to counter the aggravation of the disease. Over decades of research, to go further in the understanding of the disease and its evolution, a wide panel of genetic alterations affecting multiple genes has been highlighted. These are mainly involved in alternative splicing, epigenetic, miRNA regulation, intracellular signaling, and transcription factors expression. If JAK2 mutation, irrespective of the nature of the alteration, is known to be a crucial event for the disease to initiate, additional mutations seem to be markers of progression and poor prognosis. These discoveries have helped to characterize the complex genomic landscape of PV, resulting in potentially new adapted therapeutic strategies for patients concerning all the genetic interferences.
Mots clés
JAK2 mutation, erythrocytosis, mutational landscape, myeloproliferative neoplasm, polycythemia vera
Référence
Genes (Basel). 2022 Apr 2;13(4):
